Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380492 · ClinicalTrials.gov registry record · Phase 1
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Perceive Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT05380492 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is active but no longer recruiting, run by Perceive Biotherapeutics. The registered enrollment target is 45 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05380492, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is active but no longer recruiting, sponsored by Perceive Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
Conditions Studied
Interventions
- BIOLOGICAL VOY-101
Study Locations (3)
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Retina Consultants of Texas - Bellaire
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05380492
The ClinicalTrials.gov registry entry for NCT05380492 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The listed sponsor is Perceive Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which VOY-101 is the first listed.
NCT05380492 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05380492 about?
NCT05380492 is a clinical study titled "Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration". This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
What is the current status of trial NCT05380492?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-11-17. Estimated completion is 2025-11.
What conditions does trial NCT05380492 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.
What interventions are being tested in trial NCT05380492?
The interventions under investigation include: VOY-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05380492?
This trial is sponsored by Perceive Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05380492 being conducted?
This trial has 3 study locations across Massachusetts, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Age-related Macular Degeneration
All registered trials for this condition
Geographic Atrophy
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.